Oncolytics Receives Nasdaq Deficiency Notice After Stock Falls Below $1
Distressed
Company Background
Oncolytics Biotech is a clinical-stage immunotherapy company developing pelareorep, an investigational oncolytic virus being evaluated in squamous cell anal carcinoma, colorectal cancer, and other gastrointestinal tumors. The company generates no product revenue and funds operations entirely through equity issuances. With a market capitalization of approximately $101 million, it completed a redomestication from British Columbia to Nevada in March 2026, shifting its legal domicile to the United States.
The clinical pipeline has produced genuine momentum. In April 2026, the FDA aligned with the company on the design of a pivotal randomized study for pelareorep in squamous cell anal carcinoma. A separate Phase 2 randomized study in second-line colorectal cancer, REO 033, began enrolling patients in March 2026, with preliminary tumor response data expected by year-end. Earlier data from the REO 022 study showed a 33% objective response rate and a 19.5-month median duration of response for pelareorep combined with bevacizumab and FOLFIRI in KRAS-mutant metastatic colorectal cancer.
Despite those advances, the company's financial footing has drawn scrutiny. Ernst & Young, which audited Oncolytics through fiscal year 2025, included going-concern explanatory paragraphs in its audit reports for both the year ended December 31, 2024 and the year ended December 31, 2025 — signaling that the auditor assessed meaningful doubt about the company's ability to continue operating over the following twelve months in each of those periods.
What Was Disclosed
Oncolytics received a letter from Nasdaq's Listing Qualifications Staff on July 20, 2026, notifying it that its common stock had closed below $1.00 per share for 30 consecutive business days, putting it in breach of the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The notice has no immediate effect on trading; shares continue to trade on the Nasdaq Capital Market under the symbol ONCY.
Under Nasdaq Listing Rule 5810(c)(3)(A), the company has a 180-calendar-day compliance period — expiring January 19, 2027 — to cure the deficiency. Compliance is achieved if the stock closes at or above $1.00 for at least ten consecutive business days, though Nasdaq retains discretion to extend that threshold. If the company misses the first deadline, it may qualify for a second 180-day window, provided it meets the applicable market value of publicly held shares requirement, satisfies all other initial listing standards except the minimum bid price, and notifies Nasdaq of its intent to cure. Failure in both windows would make the stock subject to delisting proceedings.
Management said it intends to monitor the closing bid price and evaluate available options to regain compliance, without specifying whether measures such as a reverse stock split are under consideration.
Why It Matters
The deficiency notice arrives alongside two earlier stress signals documented in the company's own filings. EY's inclusion of going-concern paragraphs in the 2024 and 2025 audit reports reflects consecutive years in which the company's auditor assessed substantial doubt about its ability to fund ongoing operations. In April 2026, Oncolytics opened a $75 million at-the-market equity offering through Jefferies LLC — a structure that allows incremental share sales into the market — consistent with a company actively managing its cash runway.
On July 6, 2026 — fourteen days before the Nasdaq notice — the Audit Committee dismissed EY and engaged Baker Tilly US as the company's new auditor for fiscal 2026. The company attributed the change to its corporate restructuring, specifically the redomestication to Nevada, and reported no disagreements with EY on any matter of accounting principles, practices, or disclosure. The filings do not link the auditor change to the going-concern findings or the subsequent Nasdaq deficiency.
The clinical pipeline offers a substantive offset. The FDA granted Fast Track Designation for pelareorep in anal carcinoma on July 20, 2026 — the same day as the Nasdaq notice — following an earlier FDA alignment on pivotal study design. If the REO 033 colorectal cancer study produces positive interim data by year-end and the SCAC pivotal study advances toward enrollment, the company may be positioned to attract financing. Whether that progress materializes within the January 2027 compliance window is the critical near-term question.